- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KLOTHO NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| Mi | Klotho Clears Nasdaq Hurdle-KLTO Stock Remains On The Big Board | 1 | Benzinga.com | ||
| Mi | Klotho Neurosciences regains NASDAQ compliance | 1 | Investing.com | ||
| Mi | Klotho Neurosciences regains full compliance with Nasdaq listing standards | 2 | Seeking Alpha | ||
| Mi | Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules | 192 | PR Newswire | Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy... ► Artikel lesen | |
| 10.07. | Klotho Neurosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS | - | Investing.com | ||
| 10.07. | Klotho Neurosciences: Aktie schießt nach FDA-Sonderstatus für ALS-Therapie in die Höhe | 3 | Investing.com Deutsch | ||
| 10.07. | Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") | 77 | PR Newswire | NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative... ► Artikel lesen | |
| 30.06. | Klotho Neurosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 30.06. | Klotho Neurosciences, Inc.: Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS | 266 | PR Newswire | NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation... ► Artikel lesen | |
| 24.06. | Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population | 266 | PR Newswire | NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions... ► Artikel lesen | |
| 18.06. | Klotho Neurosciences terminates share exchange agreement with SkyBell | 4 | Investing.com | ||
| 18.06. | Klotho Neurosciences, Inc.: Klotho Neurosciences Announces Mutual Termination Of Share Exchange Agreement With Skybell Technologies, To Continue Its Focus On Therapeutics And Longevity Programs | 111 | PR Newswire | Key highlights of the announcement include:
Elimination of Future Dilution: The Company will no longer be required to issue new common stock to SkyBell, which... ► Artikel lesen | |
| 16.06. | Klotho Neurosciences raises $11 million, eliminates all debt | 1 | Investing.com | ||
| 16.06. | Klotho Neurosciences, Inc.: Klotho Neurosciences Raises Over $11 Million, Retires All Debt, And Exceeds Nasdaq Stockholders' Equity Requirement | 142 | PR Newswire | Highlights:
Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor... ► Artikel lesen | |
| 10.06. | Klotho Neurosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock? | 13 | Forbes | ||
| 09.06. | Klotho Neurosciences Stock Skyrockets 621% On Preclinical Longevity Findings | 21 | RTTNews | ||
| 02.06. | Klotho Neurosciences, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 21.04. | Klotho Neurosciences, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 27,970 | +1,47 % | wO Börsenlounge: BASF | Bayer | Steyr - drei Perlen für das Depot | Donald Trump drückt den DAX rund ein Prozent ins Minus. Seine Ankündigung von Strafzöllen in Höhe von 30 Prozent gefällt den Anlegern überhaupt nicht. Ein richtiger Grund zur Sorge besteht allerdings... ► Artikel lesen | |
| GILEAD SCIENCES | 93,99 | +0,18 % | Gilead Sciences-Aktie verliert 4,36 Prozent (93,65 €) | Am US-amerikanischen Aktienmarkt liegt das Wertpapier von Gilead Sciences zur Stunde im Minus. Das Papier kostete zuletzt 93,65 Euro. Die Aktie von Gilead Sciences verzeichnet derzeit einen Abschlag... ► Artikel lesen | |
| AURORA CANNABIS | 3,910 | -0,26 % | Stocks in Play: Aurora Cannabis Inc. | ||
| ABBVIE | 165,60 | +0,24 % | Dividendenbekanntmachungen (15.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5058 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4059 EUR ARCOSA INC US0396531008 0,05... ► Artikel lesen | |
| CANOPY GROWTH | 0,970 | +0,83 % | Down an Incredible 99% From All-Time Highs, Is Canopy Growth Stock Worth Buying Now? | ||
| ELI LILLY | 678,60 | +0,55 % | Abbott, Eli Lilly Lead Thursday's Market Cap Stock Movers | ||
| ASTRAZENECA | 119,65 | -0,66 % | Buy or Goodbye?: Meta, Hensoldt, Astrazeneca und Thyssenkrupp - Die Analystenstimmen des Tages | © Foto: Britta Pedersen/zb/dpaMeta, Hensoldt, Astrazeneca und Thyssenkrupp: So bewerten Top-Analysten die Aktien. Ein Überblick.Jefferies hebt das Kursziel für Meta an Das Analysehaus Jefferies hat... ► Artikel lesen | |
| HALO COLLECTIVE | - | - | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
| TILRAY BRANDS | 0,533 | +1,10 % | Tilray Brands, Inc.: Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink | ||
| BRISTOL-MYERS SQUIBB | 41,450 | +0,02 % | Bristol Myers Squibb, Pfizer Announce Direct-to-patient Option For Eliquis | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Pfizer (PFE) Thursday announced a direct-to-patient option for purchasing their blood thinner medicine, Eliquis through the partnership's... ► Artikel lesen | |
| TEVA | 14,100 | 0,00 % | Teva Pharma stock rating reiterated at Buy by BofA on Austedo growth | ||
| INNOCAN PHARMA | 0,130 | +0,78 % | Neue Studie: Gamechanger für Innocan Pharma?! | ||
| ABBOTT LABORATORIES | 104,00 | -0,08 % | Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction' | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
| DERMAPHARM | 34,600 | +0,14 % | Dermapharm: Viele Pläne für 2025 | Dermapharm wird 0,90 Euro je Aktie als Dividende an die Aktionäre überweisen. Das erfüllt die Erwartungen der Analysten von mwb research. Dies entspricht einer Ausschüttungsquote von 43 Prozent. Insgesamt... ► Artikel lesen |
KLOTHO NEUROSCIENCES INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLOTHO NEUROSCIENCES INC finden Sie auf Wallstreet Online.